Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michele Maio(University of Siena), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Gian Carlo Antonini Cappellini(Istituto Dermopatico dell'Immacolata), Luca Galli(University of Pisa), Francesco De Rosa(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Fabrizio Carnevale‐Schianca(Candiolo Cancer Institute), Virginia Ferraresi(Cancer Institute (WIA)), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Ruggero Ridolfi, Francesco Cognetti(Apple (Israel)), Michele Guida(Istituto Tumori Bari), Paola Queirolo, Ester Simeone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carolina Cimminiello(Fondazione IRCCS Istituto Nazionale dei Tumori), Maria Grazia Bernengo(University of Turin), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Gaetana Rinaldi(AOL (United States)), Mario Mandalà(University of Perugia)
Cited by 105
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k